Baxter International (NYSE:BAX) Price Target Raised to $24.00

Baxter International (NYSE:BAX) had its target price upped by TD Cowen from $20.00 to $24.00 in a research report released on Monday morning,Benzinga reports. The firm currently has a hold rating on the medical instruments supplier’s stock.

A number of other analysts also recently commented on the company. Barclays upped their target price on Baxter International from $25.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Weiss Ratings upgraded Baxter International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Citigroup downgraded Baxter International from a “neutral” rating to a “sell” rating and decreased their price target for the company from $19.00 to $17.00 in a report on Thursday, May 28th. Stifel Nicolaus lowered their price objective on Baxter International from $20.00 to $19.00 in a research report on Friday, May 1st. Finally, The Goldman Sachs Group raised their price objective on shares of Baxter International from $19.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Two investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $21.09.

Baxter International Trading Up 1.4%

NYSE BAX opened at $24.71 on Monday. Baxter International has a 1 year low of $15.73 and a 1 year high of $28.94. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.85 and a quick ratio of 1.23. The company has a market capitalization of $12.76 billion, a PE ratio of -11.60, a P/E/G ratio of 3.93 and a beta of 0.62. The company has a fifty day moving average of $21.05 and a 200 day moving average of $19.52.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.05. The company had revenue of $2.70 billion for the quarter, compared to the consensus estimate of $2.62 billion. Baxter International had a positive return on equity of 16.15% and a negative net margin of 9.70%.The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the firm earned $0.62 EPS. Research analysts forecast that Baxter International will post 1.91 earnings per share for the current year.

Hedge Funds Weigh In On Baxter International

Several institutional investors and hedge funds have recently modified their holdings of the business. Basepoint Wealth LLC acquired a new position in Baxter International in the 4th quarter worth about $26,000. Imprint Wealth LLC acquired a new stake in Baxter International in the third quarter valued at approximately $27,000. MUFG Securities EMEA plc acquired a new stake in Baxter International in the second quarter valued at approximately $46,000. Los Angeles Capital Management LLC purchased a new stake in shares of Baxter International in the fourth quarter valued at approximately $46,000. Finally, Versant Capital Management Inc increased its position in shares of Baxter International by 552.2% in the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier’s stock valued at $51,000 after buying an additional 2,043 shares in the last quarter. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Key Headlines Impacting Baxter International

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Analysts raised their valuation views: Stifel increased its price target to $24 from $19, TD Cowen lifted its target to $24 from $20, and UBS raised its target to $25 from $19. All three firms retained Hold or Neutral ratings, suggesting improved expectations but limited perceived upside from current levels. Stifel Adjusts Price Target on Baxter International
• Positive Sentiment: A cash-flow valuation analysis suggests Baxter may be approximately 19% undervalued, providing support for the stock’s recent strength if the company can deliver on earnings and cash-generation expectations. Baxter Stock May Be Undervalued on Cash Flow
• Neutral Sentiment: Investors are focused on Baxter’s upcoming earnings report. Medical-product demand remains resilient, but analysts warn that tariffs and inflation could pressure margins, making the company’s guidance and cost-control commentary particularly important. Medical Product Stocks Earnings Preview
• Negative Sentiment: Baxter recalled certain antibiotic intravenous bags after reports that pieces of cardboard were found floating in the solution. The recall could create costs, disrupt shipments and raise product-quality concerns, although the financial impact was not specified. Baxter Antibiotic IV Bag Recall

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.